GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (MEX:PODD) » Definitions » YoY EBITDA Growth

Insulet (MEX:PODD) YoY EBITDA Growth : 14.81% (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Insulet YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Insulet's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 14.81%.

Insulet's EBITDA per Share for the three months ended in Mar. 2025 was MXN21.81.

Insulet YoY EBITDA Growth Historical Data

The historical data trend for Insulet's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet YoY EBITDA Growth Chart

Insulet Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.13 25.51 -27.21 145.41 60.31

Insulet Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.27 46.65 58.34 48.26 14.81

Insulet YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Insulet's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(119.591-74.598)/ | 74.598 |
=60.31 %

Insulet's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (Q: Mar. 2025 )
=(EBITDA per Share (Q: Mar. 2025 )-EBITDA per Share (Q: Mar. 2024 )) / | EBITDA per Share (Q: Mar. 2024 )) |
=(21.808-18.995)/ | 18.995 |
=14.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Insulet's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Insulet Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (MEX:PODD) » Definitions » YoY EBITDA Growth
Comparable Companies
ZBH STE PEN GMED MASI DXCM BIO BRKR GKOS INSP ABT BSX SYK MDT XTER:SHL EW SZSE:300760 XAMS:PHIA XSWX:SOON SHSE:688271
Traded in Other Exchanges
PODD:USA GOV:Germany GOV:Germany
Address
100 Nagog Park, Acton, MA, USA, 01720
Website
https://www.insulet.com
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.